Retinal venous pressure in the non-affected eye of patients with retinal vein occlusions by Mozaffarieh, Maneli et al.
RETINAL DISORDERS
Retinal venous pressure in the non-affected eye
of patients with retinal vein occlusions
Maneli Mozaffarieh & M. Bärtschi & P. B. Henrich &
A. Schoetzau & J. Flammer
Received: 3 December 2013 /Revised: 6 March 2014 /Accepted: 10 March 2014 /Published online: 28 March 2014
# Springer-Verlag Berlin Heidelberg 2014
Abstract
Background To measure the retinal venous pressure (RVP) in
both eyes of patients with unilateral central retinal vein occlu-
sions and to compare these values to controls.
Methods The study included 31 patients with unilateral cen-
tral retinal vein occlusions (CRVO) and 31 controls who were
matched by age, sex, and systemic disease. RVP was mea-
sured in all patients bilaterally by means of contact lens
ophthalmodynamometry, and the RVP measurements of the
affected and unaffected eyes of patients were compared to the
RVPs of controls. Ophthalmodynamometry is done by apply-
ing an increasing pressure on the eye via a contact lens. The
minimum force required to induce a venous pulsation is called
ophthalmodynamometric force (ODF). The RVP is defined
and calculated as the sum of ODF and intraocular pressure
(IOP) [RVP = ODF + IOP].
Results The RVP group means ± SD were as follows: pa-
tient’s affected eyes (45.0±11.6 mmHg), patient’s unaffected
eyes (38.0±11.1 mmHg) ,and (17.7±6.7 mmHg) in the eyes
of controls. The values of RVP, even in the patients unaffected
eyes, were significantly higher than in the eyes of controls (P
< 0.001).
Conclusions In patients with CRVO, the RVP is increased in
both the affected as well as in the unaffected contralateral eye.
Keywords Retinal venous pressure . Central retinal vein
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Introduction
A retinal vein occlusion (RVO) is a sight-threatening disease.
It can be divided into central retinal vein occlusion (CRVO)
and a branch retinal vein occlusion (BRVO). Although differ-
ent aetiological factors [1–4] and therapeutic approaches
[5–10] have been proposed, the pathogenesis of the condition
stil l remains debatable [11–13]. In this context,
ophthalmodynamometric measurements of retinal venous
pressure (RVP) in eyes of patients with retinal vein occlusions
is of special interest.
Knowledge about the RVP of the unaffected eyes of pa-
tients with a CRVO gives hints about the possibility of sys-
temic factors being involved in the pathogenesis of the dis-
ease. For this reason, we performed this study and measured
RVP in both the affected and unaffected eyes of patients with a
CRVO. As expected, patients with a CRVO have a higher
RVP in their affected eyes [14]. To the best of our knowledge,
however, we report for the first time a significantly increased
RVP in the non-affected contralateral eyes of such patients.
Methods
Thirty-one patients with a unilateral CRVO (seven ischemic
and 24 non-ischemic) and 31 age- and sex-matched volunteers
were included in the study between January 2011 and
September 2012. Patients were recruited from the University
Eye Clinic Basel; the control subjects, who were matched by
age, sex, refractive-error, and systemic disease were recruited
in our outpatient department. Control subjects did not have
any relevant eye disease. Ethical approval was obtained from
the local medical ethics committee before entering into the
study. The study was designed and conducted in accordance
with the tenets of the Declaration of Helsinki. Included were
patients with a unilateral CRVO, confirmed with fundus
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photography as well as fluorescein angiography. There were
no exclusion criteria. At the initial work-up, all patients re-
ceived a comprehensive ophthalmic examination followed by
fundus photography and fluorescence angiography of the
retina. A blood test was done in all patients including full
blood count and lipid profiles as well as measurement of blood
coagulation factors.
For all patients and controls, RVP was measured in both
eyes by ophthalmodynamometry (Meditron GmbH,
Völklingen, Germany). This device consists of a conventional
Goldmann contact lens fitted with a pressure sensor (at its
outer margin where the Goldmann contact lens is usually held
during an ophthalmoscopic examination) connected to an
LCD screen.
Ophthalmodynamometry is done by applying an increasing
pressure on the eye via the contact lens. This applied pressure
can be read as an IOP increase on the attached LCD screen
based on a calibration curve. The calibration of the conversion
of the applied force to ΔP has been shown by Morgan et al.,
who found that the correlation between induced IOP and ODF
is strong and the relationship is linear [15]. The IOP increase
required to induce a venous pulsation is called the
ophthalmodynamometric force (ODF). If a spontaneous ve-
nous pulsation is present, ODF is said to be 0; if not, increas-
ing pressure is applied. The RVP is defined and calculated as
the sum of the ODF and IOP [RVP = ODF + IOP].
Statistical analysis
A linear mixed effects model was performed to compare
values of the RVP of the eyes with a CRVO to the contralateral
unaffected eye and to the eyes of controls. The independent
factor is “Status” (affected and unaffected eyes of patients and
eyes of controls); the dependent variable was the RVP. The
subject was treated as a random factor. To adjust for a potential
influence of the IOP, these factors were also included in the
model. Adjustment means that results are presented at a fixed
IOP value. The results are presented in Table 1 as means ± SD.
In addition, the differences with their 95 % confidence inter-
vals (CI) are reported. A P-value <0.05 was considered
significant.
Results
Table 1 depicts the values in mean and standard deviation (in
brackets) for IOP and RVP in both eyes of patients with
unilateral CRVO as well as in the controls. Eleven of the
controls had a spontaneous venous pulsation in both
eyes.Table 2 gives an overview of the demographic data of
patients and controls.
No significant differences were detected in the IOP of the
eyes of patients with a CRVO in comparison to controls. RVP
was 20.3 mmHg higher in the patients' unaffected contralat-
eral eyes in comparison to eyes of controls [confidence inter-
val (CI): 15.7 to 24.9; P<0.001]. When adjusted for IOP, RVP
was 17.7 mmHg higher in the patients' unaffected contralat-
eral eyes in comparison to eyes of controls [confidence inter-
val (CI): 13.3 to 22.1; P<0.001]. RVP was 7 mmHg higher in
the patients' CRVO-affected eyes in comparison to their unaf-
fected ‘healthy’ eyes [confidence interval (CI): 4.7 to 9.4;
P<0.001]. When adjusted for IOP, RVP was 6.9 mmHg
higher in the patients' CRVO-affected eyes in comparison to
their unaffected ‘healthy’ eyes [confidence interval (CI): 4.6 to
9.2; P<0.001].
Discussion
An increased RVP in eyes of patients with CRVO has already
been reported [14, 16] and this increase was significantly
higher in the ischemic than in the non-ischemic group [16].
To the best of our knowledge, this is the first report of an
Table 1 Descriptive statistics: age, gender, and concomitant diseases in
the two groups
Patients Controls
N 31 31
Age 62.8±14.7 62.6±13.8
Gender
Female 15 14
Male 16 17
Concomitant diseases
Arterial hypertension & hyperlipidaemia 5 8
Arterial hypertension 6 2
Hyperlipidaemia 5 0
Diabetes mellitus type 2 3 3
Primary vascular dysregulation (PVD) [12] 6 4
PVD & hypothyroidism 0 1
Hypothyroidism 2 0
Depressive disorder 1 0
Table 2 IOP and RVP measurements. Mean and SD values for IOP and
RVP in the affected and unaffected eyes of patients as well as in both eyes
of controls
Patients Controls
Affected
eye
Unaffected
eye
Right eye Left eye
Number of eyes 31 31 31 31
IOP: mean, (SD) 16.4 (3.93) 16.6 (3.96) 13.6 (3.84) 13.8 (3.86)
RVP: mean, (SD) 45.0 (11.6) 38.0 (11.1) 16.3 (7.5) 17.3 (6.7)
IOP Intraocular pressure, RVP Retinal venous pressure
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increased RVP in the patient’s unaffected contralateral eyes
which is statistically significant and, from our point of view,
also clinically relevant.
At present, the cause of this increase is not known and
needs to be clarified by other studies. There are two potential
explanations: (a) the underlying eye disease affects both eyes
of such patients but becomes clinically manifest only in the
more severe affected eye, or (b) the RVP increase is due to
systemic factors such as increased level of endothelin-1, as has
been found in vascular occlusive diseases [17, 18]. The
endothelin-1 can either come from the circulating blood [19]
where it can diffuse through the fenestrated capillaries of the
choroid to the optic nerve head (not fully protected by a
barrier), or it can be produced by the atherosclerotic altered
arteries [20], and finally it can also be produced locally along
with other molecules such as VEGF by hypoxic tissues [21].
In conclusion, our results raise the question, whether a
venous thrombus is indeed the primary cause of RVO. These
results rather support the assumption that a functional con-
striction of the vein may be involved [11–13].
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